SCHEMBL8380740

SCHEMBL8380740

FCCn1cc(-c2cccc(OCC3CC3)c2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.44
FGFR2 P21802 2/20 0.44
FGFR4 P22455 2/20 0.44
FGFR3 P22607 2/20 0.44
KDR P35968 2/20 0.44
BACE1 P56817 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
KCNH2 Q12809 3/20 0.42
LRRK2 Q5S007 1/20 0.42
NR1H4 Q96RI1 1/20 0.40
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
CHRNB1 P11230 2/20 0.40
CHRNB2 P17787 2/20 0.40
CHRNB4 P30926 2/20 0.40
CHRNA3 P32297 2/20 0.40
CHRNB3 Q05901 2/20 0.40
FFAR1 O14842 1/20 0.39
PPARD Q03181 1/20 0.39
IGF1R P08069 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13283629 0.85 LRRK2 (0.43) BACE1FFAR4KCNH2LRRK2NR1H4
SCHEMBL8377007 0.85 KCNH2 (0.43) BACE1FFAR4KCNH2LRRK2NR1H4
SCHEMBL3577431 0.81 CHRNB2 (0.39) CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3
SCHEMBL13440413 0.80 EGLN1 (0.46) FFAR4KCNH2IGF1R
SCHEMBL8377611 0.77 L3MBTL1 (0.40) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL13757017 0.71 L3MBTL1 (0.61) KDRKCNH2
SCHEMBL3579985 0.71 BACE1 (0.66) BACE1
SCHEMBL8383285 0.69 BACE1 (0.56) BACE1KCNH2
SCHEMBL29404107 0.66 FEN1 (0.46) BACE1KCNH2PRMT5WDR77
SCHEMBL3582705 0.66 CHRNB2 (0.41) LRRK2CHRNB1CHRNB2CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168106-A1 Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation WYETH LLC (US) 2010-07-01 US disclosed
US-7705030-B2 Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation WYETH LLC (US) 2010-04-27 US disclosed
US-20080306091-A1 AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION WYETH (US) 2008-12-11 US disclosed
US-7417047-B2 Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation WYETH (US) 2008-08-26 US disclosed
US-20070004786-A1 Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation WYETH (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004786-A1 Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation BACE1, BACE2, APP FGFR1 3385/4885FGFR2 2537/4885FGFR4 3084/4885
US-20080306091-A1 AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION BACE1, BACE2, APP FGFR1 3385/4885FGFR2 2537/4885FGFR4 3084/4885
US-20100168106-A1 Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation BACE1, BACE2, APP FGFR1 3745/4885FGFR2 2881/4885FGFR4 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.